Interestingly, in pancreatic cancer it has been shown that YAP/TAZ can compensate for activating mutations in the classical oncogenic driver, KRAS, suggesting a means for the cancer to bypass oncogenic MAPK signalling and the associated therapeutic approaches [97], highlighting the need for therapies targeted at YAP/TAZ for cancer. The gene discussed is YAP1; the disease is pancreatic neoplasm.